Actively Recruiting
Precision Medicine in the Prostate Cancer Care Pathway
Led by Institute of Cancer Research, United Kingdom · Updated on 2025-12-16
3000
Participants Needed
1
Research Sites
824 weeks
Total Duration
On this page
Sponsors
I
Institute of Cancer Research, United Kingdom
Lead Sponsor
R
Royal Marsden NHS Foundation Trust
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.
CONDITIONS
Official Title
Precision Medicine in the Prostate Cancer Care Pathway
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men aged between 30 and 70 years
- Diagnosed with prostate cancer before age 60 or
- Diagnosed with metastatic castration resistant prostate cancer at any age or aggressive prostate cancer with Gleason score 4+4 or higher under 70 years
- Have a family history of prostate cancer defined as three or more cases in first or second degree relatives at any age
You will not qualify if you...
- WHO performance status 4
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Royal Marsden Hosital,
Sutton, England, United Kingdom, SM2 5PT
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here